GPC3-CAR-T Cells for the Hepatocellular Carcinoma

NCT ID: NCT04506983

Last Updated: 2022-02-14

Basic Information

• Recruitment Status: SUSPENDED
• Clinical Phase: PHASE1
• Total Enrollment: 12 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-06-10
• Study Completion Date: 2023-10-10

Brief Summary

This is a single center, single arm, open-label, phase I study to evaluate the safety and efficacy of GPC3-CAR-T cells in patients with hepatocellular carcinoma.

Detailed Description

GPC3-CAR-T cells is a novel CAR-T cells which designed for the cell membrane protein Glypican-3. Patients with hepatocellular carcinoma will be enrolled, and GPC3-CAR-T cells will be intravenously infused with a escalated dose of 1×106, 3×106, 10×106 GPC3-CAR-T cells. Tumor markers and GPC3-CAR-T cell proliferation will be monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14, day 28). The aim of this clinical trial is to evaluate the safety and efficacy of GPC3-CAR-T cells therapy in patients with hepatocellular carcinoma. The primary endpoint is the safety of CAR-T cells including the effect ratio of CRS and ICANS, ORR. The secondary endpoint is the CAR-T ratio and CAR gene copied number in PB, PFS, OS and DOR.

Conditions

Hepatocellular Carcinoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

GPC3-CAR-T cells

Patients with hepatocellular carcinoma will be enrolled, and GPC3-CAR-T cells will be intravenously infused with a escalated dose of 1×106 /3×106/10×106GPC3-CAR-T cells. Tumor markers and GPC3-CAR-T cell proliferation will be monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14,day 21, day 28).

Group Type: EXPERIMENTAL

GPC3-CAR-T cells

Intervention Type: BIOLOGICAL

Patients with hepatocellular carcinoma will be enrolled, and GPC3-CAR-T cells will be intravenously infused with a escalated dose of 1×106 /3×106/10×106GPC3-CAR-T cells.

Interventions

GPC3-CAR-T cells

Patients with hepatocellular carcinoma will be enrolled, and GPC3-CAR-T cells will be intravenously infused with a escalated dose of 1×106 /3×106/10×106GPC3-CAR-T cells.

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. Age ≧18years, gender unlimited.

2. Failure or intolerance after at least first-line treatment.

3. GPC3 positive(IHC)

4. Patients must have at least one target lesion available for evaluation.

5. BCLC B or C.

6. Child-Pugh grade A or B

7. ECOG is 0 or 1 (one week before enrollment.)

8. Estimated life expectancy ≥ 3 months.

9. Functioning of major organs are normal.

10. Women of childbearing age (15-49 years old) must receive a pregnancy test within 7 days prior to initiation of treatment and the results are negative; male and female patients with fertility must use an effective contraceptive to ensure 3 months after discontinuation of treatment during the study period not pregnant inside.

11. Patients who voluntarily sign informed consent and are willing to comply with treatment plans, visit arrangements, laboratory tests and other research procedures.

Exclusion Criteria

1. There are uncontrollable active infections that need systemic treatment.

2. HIV antibody is positive or syphilis antibody is positive.

3. Pregnant or lactating women.

4. hepatic encephalopathy.

5. patients with organ failure:

• Heart: NYHA heart function grade IV;
• Liver: Grade C that achieves Child-Turcotte liver function grading;
• Kidney: kidney failure and uremia;
• Lung: symptoms of respiratory failure;
• Brain: a person with a disability.

6. It is undergoing systemic hormones therapy.

7. Impact results show that over 50% of the liver is occupied by tumor .

8. Patients who are still in the observation stage of other antitumor drugs 30 days before blood collection.

9. Patients were received other gene therapy products, or are participating in other clinical trials within 4 weeks prior to cell infusion.

10. Abnormal thyroid function ≧Level 3.

11. Active autoimmune diseases require systemic treatment during the first two years of screening.

12. Patients have mental illness or history of drug abuse.

13. Patients are participating in other clinical studies.

14. The researchers found that it was unsuitable for the recipients to be enrolled.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

China Immunotech (Beijing) Biotechnology Co., Ltd.

INDUSTRY

Sponsor Role: collaborator

Beijing Tsinghua Chang Gung Hospital

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Gong Li, M.A.

Role: STUDY_DIRECTOR

Beijing Tsinghua Changgeng Hospital

Locations

Beijing Tsinghua Changgung Hospital

Beijing, Beijing Municipality, China

Countries

China

Other Identifiers

HXYT-009

Identifier Type: -

Identifier Source: org_study_id